A review of present management of castrate resistant prostate cancer

Abstract

Prostate cancer is the most common cancer among Sub-Saharan Africans. Androgen deprivation therapy remains the mainstay for the management of advanced prostate cancer. However, treatment failure is the rule after a predictable response to androgen deprivation with subsequent development of castrate resistant prostate cancer.Several pathways in the propagation of castrate resistant prostate cancer have been elucidated,thus leading to development of novel agents in the management of this otherwise lethal disease.Importantly, most of these cellular alterations still require the presence of some, albeit lower, androgen concentrations. Consequently, it is recommended that ADT be continued for the remainder of a patient's life. This review gives a summary of the current and approved treatment options for castrate resistant prostate cancer.

Keywords: Castrate, resistant, prostate cancer, cytotoxic therapy, Immunotherapy, antiandrogen therapy